X
CRSP icon

Xponance’s CRISPR Therapeutics CRSP Stock Holding History

Xponance’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501K Buy
9,182
+746
+9% +$39.3K ﹤0.01% 1099
2026
Q1 		$401K Buy
8,436
+1,524
+22% +$80.4K ﹤0.01% 1109
2025
Q4 		$362K Buy
6,912
+416
+6% +$24.9K ﹤0.01% 1082
2025
Q3 		$421K Buy
6,496
+47
+0.7% +$2.7K ﹤0.01% 1027
2025
Q2 		$314K Buy
+6,449
New +$250K ﹤0.01% 1123

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Xponance's CRSP Position: Q2 2026 in Review

Xponance increased its CRISPR Therapeutics (CRSP) stake by 8.8% in Q2 2026, buying an estimated $39.3K and bringing the position to 9,182 shares worth $501K. The position accounts for ﹤0.01% of the portfolio, ranked #1099.

Xponance first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Xponance held 9,182 shares of CRISPR Therapeutics worth $501K as of Q2 2026.
  • Xponance bought 746 CRISPR Therapeutics shares in Q2 2026, an estimated $39.3K.
  • CRISPR Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1099 holding.
  • Xponance first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.